0001567619-21-019350.txt : 20211104 0001567619-21-019350.hdr.sgml : 20211104 20211104172519 ACCESSION NUMBER: 0001567619-21-019350 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 EFFECTIVENESS DATE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sands Capital Ventures, LLC CENTRAL INDEX KEY: 0001846444 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-21032 FILM NUMBER: 211381242 BUSINESS ADDRESS: STREET 1: 1000 WILSON BOULEVARD, SUITE 3000 CITY: ARLINGTON STATE: VA ZIP: 22209 BUSINESS PHONE: 703-562-4000 MAIL ADDRESS: STREET 1: 1000 WILSON BOULEVARD, SUITE 3000 CITY: ARLINGTON STATE: VA ZIP: 22209 13F-HR 1 primary_doc.xml 13F-HR LIVE false true false 0001846444 XXXXXXXX 09-30-2021 09-30-2021 Sands Capital Ventures, LLC

1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209

13F HOLDINGS REPORT 028-21032 Y The Reporting Manager does not serve as adviser to all of the owners of, or have formal investment discretion with respect to, the securities reported herein, but may be deemed to be part of a group of affiliated persons exercising investment discretion with respect to such securities. The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, or for any other purpose, that the Reporting Manager or any other manager with respect to the securities listed herein exercises investment discretion or is a member of, or is otherwise affiliated with, such a group with respect to such securities. Reference is made, where relevant, to reports filed under Sections 13(d), 13(g) and 16(a) of the Exchange Act for additional information with respect to such beneficial ownership and/or pecuniary interest of the Reporting Manager, any other manager with which it may share or be deemed to share investment discretion and related entities. The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Exchange Act, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person is the beneficial owner of any securities. Jonathan Goodman 703-562-4000 /s/ Jonathan Goodman Arlington VA 11-04-2021 0 13 663025 false INFORMATION TABLE 2 form13fInfoTable.xml 908 DEVICES INC COM 65443P102 10615 326427 SH SOLE 326427 0 0 ABSCI CORP. COM 00091E109 672 57804 SH SOLE 57804 0 0 ACUMEN PHARMACEUTICALS, INC COM 00509G209 50778 3417075 SH SOLE 3417075 0 0 CANDEL THERAPEUTICS, INC COM 137404109 8622 795376 SH SOLE 795376 0 0 DICE THERAPEUTICS, INC. COM 23345J104 103129 3148970 SH SOLE 3148970 0 0 DOORDASH INC COM CL A 25809K105 129812 630217 SH SOLE 630217 0 0 KARUNA THERAPEUTICS, INC. COM 48576A100 32772 267895 SH SOLE 267895 0 0 REPLIGEN CORP. COM 759916109 6515 22544 SH SOLE 22544 0 0 SNOWFLAKE INC COM CL A 833445109 95742 316576 SH SOLE 316576 0 0 SPRUCE BIOSCIENCES INC COM 85209E109 4730 787007 SH SOLE 787007 0 0 TARSUS PHARMACEUTICALS INC COM 87650L103 5603 260000 SH SOLE 260000 0 0 TAYSHA GENE THERAPIES INC COM 877619106 13497 724873 SH SOLE 724873 0 0 UIPATH INC COM CL A 90364P105 200538 3811779 SH SOLE 3811779 0 0